Table 2.
Isotyping and domain mapping of serum and CSF IgGs from LE patients using flow cytometry and cell binding assays.
| Patient | Serum |
CSF |
||
|---|---|---|---|---|
| Isotypes | Domain mapping | Isotypes | Domain mapping | |
| LEI | IgGl, IgG2 > IgG3, IgG4 | Multiple | IgGl, IgG4 | Multiple |
| LE2 | IgGl > IgG4 | Multiple | IgGl > IgG4 | Multiple |
| LE3 | IgG4 | Discoidin-LNGl | IgG4 | Discoidin-LNGl |
| LE4 | IgG2 > IgGl, IgG4 | Multiple | IgGl | Discoidin-LNGl |
| LE5 | IgG4 > IgGl | Multiple | IgG4 > IgGl | Multiple |
| LE6 | IgG4 | Discoidin-LNGl | IgG4 | Discoidin-LNGl |
| LE7 | IgG4 > IgGl | Discoidin-LNGl | IgGl, IgG4 | Discoidin-LNGl |
HEK cells were transfected with full-length or Δ1-, Δ2-, Δ3-, and Δ4-deleted Caspr2 constructs and were surface-labeled for the HA epitope. Sera at 1:500 dilution were analyzed for IgG1–IgG4 isotypes and CSF at 1:20 dilution for IgG1 and IgG4.